Products
Pre-Made Efineptakin Alfa Biosimilar, Fusion Protein targeting IL7R fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting CD127/CDW127 for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-816
Pre-Made Efineptakin Alfa Biosimilar, Fusion Protein targeting IL7R fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting CD127/CDW127 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Efineptakin alfa A long-acting immunoglobulin (Ig) fusion protein composed of a recombinant form of the endogenous human protein interleukin-7 (rhIL-7) and fused to a hybrid Fc (hyFc) region of a human antibody, with hematopoietic and immunopotentiating activities. Upon administration of efineptakin alfa, IL-7 stimulates the proliferation, differentiation, trafficking and survival of a variety of T-cell subsets, including naive, central memory (CM), effector memory (EM), terminally differentiated effector memory (TEMRA) and natural killer (NK) T cells, and enhances T-cell-mediated anti-tumor immune responses.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-816-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-816-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-816-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-816-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Efineptakin Alfa Biosimilar, Fusion Protein targeting IL7R fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting CD127/CDW127 |
| INN Name | Efineptakin Alfa |
| Target | IL7R |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - [IL7 (interleukin 7, IL- 7)]1 - IGHG4 Fc (Fragment constant) |
| VD LC | Fusion - [IL7 (interleukin 7, IL- 7)]1 - IGHG4 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Genexine (Seongnam South Korea) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
